摘要
目的探讨真武汤联合腹腔化疗治疗脾肾阳虚型癌性腹水的效果。方法分析我院2015年1月~2017年1月收治的50例脾肾阳虚型癌性腹水患者临床资料,依据治疗方式不同进行分组,对照组(顺铂、氟尿嘧啶化疗)20例和观察组(顺铂、氟尿嘧啶化疗联合真武汤)30例。观察两组患者的T细胞亚群、NK细胞数、临床疗效、不良反应发生情况。结果观察组患者的CD4+、CD3+、CD8+、CD4+/CD8+和NK细胞数、临床治疗总缓解率均高于对照组,血液学毒性、胃肠道反应、肝功能损害、肾功能损害、黏膜溃疡发生率均低于对照组,差异有统计学意义(P<0.05)。结论真武汤联合腹腔化疗治疗脾肾阳虚型癌性腹水可提高机体免疫功能,总缓解率较高,不良反应少,值得临床推广应用。
Objective To investigate the effect of Zhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleen and kidney yang deficiency type.Methods The clinical data of 50 patients with carcinomatous ascites identified as spleen and kidney yang deficiency type treated in our hospital from January2015 to January 2017 were analyzed.According to the different treatment methods,20 patients in the control group were treated with Cisplatin and Fluorouracil chemotherapy and the rest was classified into the observation group given Cisplatin and Fluorouracil chemotherapy plusing Zhenwu Decoction.T cell subsets,NK cells,clinical efficacy and the incidence of adverse reactions in the two groups were observed.Results The amount of CD4＋,CD3＋,CD8＋,CD4＋/CD8＋and NK cells,and total clinical remission rate in the observation group were all higher than those in the control group and the incidence of adverse reactions such as hematological toxicity,gastrointestinal reaction,liver function damage,renal function damage,and mucosal ulcer was lower than that in the control group,with a statistical difference（P〈0.05）.Conclusion Zhenwu Decoction combined with intraperitoneal chemotherapy in the treatment of carcinomatous ascites of spleen-kidney yang deficiency type can improve the organismic immune function with a high remission rate and few adverse reactions,which is worthy of clinical application and promotion.
作者
骆嘉华
刘振海
李增辉
LUO Jia-hua;LIU Zhen-hai;LI Zeng-hui(Department of Oncology,Chenxinghai Hospital of Zhongshan City,Guangdong Province,Zhongshan 528415,China)
出处
《中国当代医药》
2018年第11期145-147,共3页
China Modern Medicine
关键词
真武汤
腹腔化疗
脾肾阳虚型
癌性腹水
Zhenwu Deeoetion
Intraperitoneal chemotherapy
Spleen and kidney yang deficiency type
Carcinomatous ascites
